Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-04-29 20:05 EST

Pulmonx Reports First Quarter 2026 Financial Results

Stock data

Close: 2.05 USD
Market cap: 68M USD
Exchange: NASDAQ
Sector: MedTech
Location: United States

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Related news

Pulmonx Reports Second Quarter 2026 Financial Results

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance

CVRx Reports Second Quarter 2026 Financial and Operating Results

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

Pulmonx